Peripheral T-cell lymphomas (PTCL) are a rare and heterogeneous subset of lymphomas with a poorer prognosis compared with B-cell lymphomas. We conducted a retrospective study of 82 patients who received high-dose therapy for PTCL (autologous SCT (ASCT) N ¼ 64; allogeneic SCT (Allo-SCT) N ¼ 18). With a median follow-up from ASCT of 37 months from transplant, 33 patients were alive; 20 died of progressive disease, 10 died from non-relapse mortality (NRM) with 1 unknown cause. Three-year overall survival (OS) and progression-free survival (PFS) were 53% (95% confidence interval (CI) 42, 67) and 50% (95% CI 39, 64), respectively. Factors significantly affecting OS and PFS on univariate analysis were histological subtype and chemotherapy sensitivity. In a multivariate analysis, the only factor with significant impact was chemotherapy sensitivity. After a median follow-up from Allo-SCT of 57 months, five patients were alive; five died of progressive disease and eight died from NRM. The 3-year OS and PFS were 39% (95% CI 22, 69) and 33% (95% CI 17, 64), respectively, and the 3-year relapse rate was 28% (95% CI 6, 50). These results demonstrate that high-dose chemotherapy with autologous stem cell rescue has a substantial role in the management of T-cell lymphoma. The use of full-intensity allogeneic transplantation is limited by high transplant-related mortality, and exploration of reduced intensity regimens is warranted.
Introduction
Non-Hodgkin's lymphoma with a T-cell phenotype, also referred to as peripheral T-cell lymphoma (PTCL), accounts for only 15% of lymphomas in Europe and North America, though it is relatively common in the Far East.
1 PTCLs are a rare and heterogeneous group of malignant disorders and most studies demonstrate a poorer prognosis associated with T-cell compared with B-cell phenotype, with T-cell phenotype being previously demonstrated to be an independent adverse risk factor in all groups except for anaplastic lymphoma kinase-positive tumours. [2] [3] [4] [5] Patients with PTCL treated with conventionaldose chemotherapy alone, demonstrated a 5-year survival of 38% (95% confidence interval (CI), 35-54%) compared to patients with B-cell disease who demonstrated a 5-year survival of 63% (95% CI 53-73%, P ¼ 0.001), a difference that was maintained when stratified using the IPI and MD Anderson tumour score. 4, 6 Cumulative experience has shown that high-dose chemotherapy is an effective salvage therapy in B-cell malignant lymphoma. 5 However, data examining the impact of high-dose chemotherapy with autologous haemopoietic stem cell rescue in PTCL are limited. In the relapse setting, 3-year event-free and overall survivals (OSs) of 37-50% and 43-48% have been reported, while when autologous stem cell transplantation (ASCT) is incorporated in the first-line treatment strategy, 3-year event-free and OSs of 48-79% and 58-80% have been achieved. However, the numbers of patients in the various studies are relatively small. [6] [7] [8] These results are similar to a comparable group of patients with B-cell lymphomas. 7, 9 The role of allogeneic stem cell transplantation (Allo-SCT) for the treatment of relapsed lymphoma remains unclear, although it has been demonstrated to be an effective salvage strategy in selected patients. 10 Although in one study Allo-SCT using a full-intensity (myeloablative) conditioning regimen was shown to have curative potential, the associated nonrelapse mortality (NRM) was exceedingly high (40-50%).
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During the last 7 years, the use of reduced-intensity conditioning regimens (RIC) (non-myeloablative) has increased across the haematological and non-haematological disease spectrum, both in the first-line and relapsed settings. Early reported results for using RIC regimens in PTCL are encouraging. 12 Taken together, results to date suggest that while PTCLs have a poor prognosis with conventional-dose chemotherapy, the use of ASCT and possibly Allo-SCT may reduce the negative impact on OS of a T-cell phenotype.
This study represents a collaborative retrospective case analysis of patients undergoing ASCT for malignant lymphoma with a T-cell phenotype. The primary aim was to determine the impact of ASCT on disease responsiveness and freedom from progression. In addition, we aimed to examine the impact of prognostic factors including the International Prognostic Index. We also report on a small number of FI Allo-SCT in PTCL.
Patients and methods
Patients with PTCL (according to the WHO lymphoma classification) were identified from the retrospectively collected national transplant registry databases of the British Society of Bone Marrow Transplantation (BSBMT) and the Australasian Bone Marrow Transplant Recipient Registry (ABMTRR). Histological diagnosis as recorded in the databases was validated at source through the transplant centre. Between 1990 and 2002, 82 patients underwent ASCT (N ¼ 64) and full-intensity Allo-SCT (N ¼ 18) as planned treatment for PTCL in the United Kingdom, Australia and New Zealand. Incomplete data sets were sent to individual transplant centres by mailed questionnaires for case record data extraction. The collected data were centrally analysed (SF, RP and GC).
The following data were collected from patients identified on the registries: age, sex, histological classification (WHO), ALK status (ALC sub-type), immunophenotype, stage, extra nodal sites, bulk disease (410 cm), B symptoms, performance status (WHO), organ involvement, laboratory parameters (LDH, b 2 microglobulin, anaemia, thrombocytopenia, eosinophilia, hypogammaglobulinaemia) and IPI score. Key variables in relation to the ASCT/Allo-SCT were collected, and included the number of lines of treatment before transplant, disease status at transplant, graft source (PBSC vs BM, sibling vs unrelated donor), transplant regimen, transplant-related morbidity and mortality, and disease response and progression-free survival (PFS). Relapsed disease was defined as clinical and/or radiological disease progression at least 1 month after either a partial or complete response, and primary refractory disease was defined as progression within 1 month after completion of chemotherapy.
Statistical analysis
OS and PFS were assessed by Kaplan-Meier survival analysis, relapse rate and transplant-related mortality by cumulative incidence analysis. 13 Factors influencing OS and PFS, transplant-related mortality and relapse rate were assessed. All relevant clinical factors were put into the models to determine if they impacted upon the chance of survival. Cox proportional hazard regression models were used for OS and PFS. The factors assessed for effect on OS and PFS after ASCT included patient gender and age, performance status at transplant, stage at diagnosis, histology, bone marrow involvement, bulk disease, extranodal sites, skin involvement, hepatomegaly, splenomegaly, IPI score, haemoglobin, disease status at transplant and time from diagnosis to transplant. The R software package was used for all statistical analysis described (R development core team, 2005). Significant factors (Po0.05) in univariate models of OS or PFS were included in a multivariate Cox model.
Results

Autologous transplantations
Patient characteristics and treatment. Patient characteristics are illustrated in Table 1 . Sixty-four patients underwent ASCT for T-cell lymphoma. The median age was 45 years (range 17 to 70) and 32 (50%) were male. Thirty patients (47%) suffered from PTCL not otherwise specified (PTCL-NOS) and 20 patients (31%) from anaplastic largecell lymphoma (ALCL). The median number of previous treatment modalities before autograft was 2 (range 1-7). For patients with ALCL (N ¼ 23), the ALK status was positive in 18% and negative in 18%, but the ALK status was not known in 64% of patients. Immunophenotypic analysis of patient disease was available in 70% of patients and the HTLV-1 serological status was not available in five of the ten patients with T-cell leukaemia/lymphoma. Where available, one patient was seropositive and four patients were seronegative. Of interest, one patient with ALCL was found to be HTLV-1 seropositive.
Pre-transplant therapy was heterogeneous, but 44 (54%) received CHOP or CHOP-like regimens. The median time from diagnosis to transplant was 10 months (range 3-162 months). Disease status at transplant was CR1 48%, CR2 6%, PR 23% and 22% with progressive disease. Ninety-five percent were transplanted with peripheral blood stem cells and 5% with bone marrow. Conditioning regimens varied although the majority (53%) received BEAM (BCNU, Etoposide, Cytarabine, Melphalan) or BEAM-like regimens, and only 12.5% received TBI-based conditioning regimens.
Toxicity and NRM. The D þ 100 and D þ 365 NRM were 9 and 14%, respectively. Thirty-one patients (48.4%) have died, with a median time to death of 6.7 months (range 1-50) post-transplant. The cause of death was progressive disease in 20 (67%), sepsis in 4 (12.9%), pneumonia/ respiratory failure in 6 (16.1%) patients, including 1 patient with fungal pneumonia and 1 patient with pneumocystis carinii pneumonia. The cause of death was unknown in one patient. Of those who died, seven patients (22.5%) died in remission.
Disease response and survival. The median follow-up was 48 months (range 4.5-131 months) from diagnosis and 37 months (range 0.03-99 months) from transplant. The median OS was 52.5 months and median PFS was 34 months ( Figure 1 ). The 3-year OS and PFS were 53% (95% CI 42, 67) and 50% (95% CI 39, 64), respectively. For those receiving ASCT as consolidation of initial response (CR1, N ¼ 31) the 2-year OS and PFS were 62 and 59%, respectively. In comparison, for those patients receiving ASCT as consolidation therapy for relapsed disease (CR2/ PR/SD, N ¼ 20), the 2-year OS and PFS were 49% each with 2-year OS and PFS for those transplanted with refractory disease (N ¼ 13) being 34 and 37%, respectively ( Figure 2 ). To date, 26 patients (40%) have relapsed posttransplant with a 3-year relapse rate of 32% (95% CI 20, 44) .
By univariate analysis, the factors that significantly affected OS and PFS at 3 years were histological subtype and chemotherapy sensitivity ( Table 2) . Patients with PTCL-NOS had a significantly worse OS (36%) and PFS (36%) at 3 years in comparison to other histological groups (69%, P ¼ 0.013; and 61%, P ¼ 0.018, respectively), while patients with ALCL had a significantly better 3-year OS (60%, P ¼ 0.04). Patients with chemotherapy-sensitive disease at the time of transplant had a highly significant improved 3-year OS (58 vs 36%, P ¼ 0.007) and PFS (53 vs 38%, P ¼ 0.014) in comparison to patients with chemotherapy-resistant disease (Figure 3 ). Factors such as age, sex, performance status and stage at diagnosis did not significantly influence OS and PFS in this analysis. There was insufficient information available on 28 patients to effectively assess the influence of the IPI score. In a multivariate analysis, both histological type (PTCL-NOS vs 'other') and chemotherapy-sensitive disease demonstrated a significant impact on both OS (P ¼ 0.01 and 0.0055, respectively) and PFS (P ¼ 0.025 and 0.046, respectively).
Allogeneic transplantation
Patient characteristics and treatment. Only 18 patients received full-intensity allogeneic transplants. Patient characteristics are illustrated in Table 1 . Median age was 28 years (range 12-52) and 14 (78%) were male. Nine patients (39%) had PTCL-NOS and three (17%) had ALCL. Seventy-eight percent (14 patients) were stage 4 at diagnosis and 65% (11 patients) had bone marrow involvement. Seventy-two percent of patients had involvement of Transplantation in T-cell lymphomas S Feyler et al extra-nodal sites at diagnosis and 79% bulky disease. Performance status at transplant was 0/1 in 75% of patients. The median number of pre-transplant treatment modalities was 2 (range 1-7), including two patients who had received a prior ASCT. Thirty-three percent received TBI based and 67% received chemotherapy-only conditioning regimens including BEAM, Busulphan/Cyclophosphamide and Fludarabine/Melphalan. Two patients receiving BEAM and one patient receiving Fludarabine/ Melphalan were also treated with Alemtuzamab during conditioning. Patients were supported by grafts from fully compatible siblings (13 patients), matched unrelated donors (4 patients) or a haploidentical donor (1 patient). Graftversus-host-disease (GvHD) prophylaxis was Cyclosporine A (CSA) and short-course Methotrexate in 11 patients, CSA and steroids in 2 patients, CSA alone in 4 cases and ATG and CSA in 1 patient.
Toxicity and NRM. The D þ 100 and D þ 365 NRM were 38% for each. Twelve patients experienced grade 0/I acute GvHD and six patients suffered from grade II-IV acute GvHD (grade III and IV, N ¼ 5). Only two cases of limited, and one case of extensive chronic GvHD were reported. Thirteen patients died with a median time to death of 2.8 months post-graft. The cause of death was progressive disease in five patients, acute GvHD in three patients, secondary malignancy in one patient and sepsis in four patients. Of those who died, eight patients (61.5%) died in remission of their disease.
Disease response and survival. The median follow-up was 37 months (range 3-99 months) from diagnosis, and 57 months (range 47-89.4 months) post-graft. The median OS and PFS are 2.5 and 2 months, respectively. The 3-year OS and PFS were 39% (95% CI 22, 69) and 33% (95% CI 17, 64), respectively ( Figure 4) . The 3-year relapse rate was 28% (95% CI 6, 50). However, there was a high transplantrelated (non-relapse) mortality of 39% (95% CI 15, 69) at 3 years, with three patients (17%) who died of acute GvHD, four (22%) of infective causes such as sepsis and pneumonia and one patient died of a second malignancy.
Discussion
PTCL is a heterogeneous group of malignant lymphomas with a generally poorer response to conventional chemotherapy compared to lymphomas with a B-cell phenotype. Many patients with this diagnosis do not proceed to high-dose chemotherapy/radiotherapy and ASCT. We demonstrate that in a selected group of patients with PTCL (those undergoing ASCT), the 3-year OS was 53%, which compares favourably with patients undergoing similar treatment programmes for both PTCL and B-cell disease as reported in other, smaller studies. [7] [8] [9] [10] Several small, uncontrolled trials have attempted to evaluate the role of ASCT in PTCL, either in the relapsed setting or as consolidation following conventional-dose primary therapy. In the relapsed setting, previous reports have demonstrated that patients with chemotherapy-sensitive disease respond favourably to ASCT, with long-term survival rates of approximately 35-45%. 7, 8, 10 We demonstrate similar OS (53%) and PFS (50%) in our study, and on multivariate analysis, chemotherapy sensitivity was the only factor to significantly impact upon outcome (Table 3) . In many studies, the success rate following ASCT varies with the pre-transplant IPI and by histological subtype, with ALCL demonstrating consistently superior salvage rates than PTCL-NOS. 7, 8, 14, 15 Although IPI did not affect outcome in our study, we were able to confirm the favourable impact of ALCL subtype. It has been suggested that such favourable results in ALCL may not necessarily extend to ALK negative ALCL -as one small study has suggested poor outcome with ASCT in this population. 5 Unfortunately, we were unable to investigate this issue further as two-thirds of patients with ALCL did not have immunohistochemistry for ALK performed, and thus the impact of ALK status on outcome could not be assessed.
Several investigators have attempted to use ASCT as part of 'up-front' therapy. 14, 16, 17 We report that for those receiving ASCT as consolidation of initial response (CR1, N ¼ 31) the 2-year OS and PFS were 64 and 61%, respectively. Fanin et al. 18 have reported 37 patients who were transplanted in CR1 with an encouraging 5-year OS of 80%. However, the population evaluated was younger (median age 31) and only included patients with ALCL, a group associated with an improved outcome when ASCT is used in CR1. Another prospective study evaluated 24 patients with PTCL undergoing ASCT in CR1; 17 with a median follow-up of 15 months, 16 of the 21 patients remained in remission. Jantunen et al. 15 in a retrospective study of 37 patients demonstrated a trend to improved 5-year OS when patients received ASCT as consolidation of CR1/PR1 over patients with relapsed and refractory disease (63 vs 45%, respectively). Most recently, Kewalramani et al. 9 reported in a retrospective analysis of 24 patients a 5-year OS and PFS of 33 and 24%, respectively, in patients with chemotherapy-sensitive disease. This did not differ significantly from a comparable group of patients with diffuse large B-cell lymphoma. However, in the absence of randomized trials proving superiority over conventional chemotherapy, the use of ASCT in the primary treatment remains speculative. Studies investigating this strategy are required particularly stratifying patients according to histological subtype and ALK expression.
The role of Allo-SCT in the management of B-cell lymphoma is still under clinical investigation, although promising early experience is encouraging. 19 Indeed, although Allo-SCT has been used as salvage therapy for indolent and high-grade malignant B-cell lymphomas, 19, 20 experience in PTCL is limited to small series of highly selected patients. 21 Dhedin et al. 22 have reported a retrospective analysis of Allo-SCT for malignant lymphoma which included 16 patients (of 73) with T-cell phenotype and reported a 5-year OS and PFS of 41 and 40%, respectively (for the group as a whole), and multivariate analysis did not identify immunophenotype or histological classification as having an effect on survival. It is possible, however, that because of the small numbers of PTCL in that study, any effect of immunophenotype/histological classification may have been masked. In our study, the 18 patients receiving full-intensity Allo-SCT achieved a 3-year OS and PFS of 39 and 33%, respectively. Due to the small number of patients and also differences in patient A significant finding from our study was the high NRM of full-intensity Allo-SCT of 39% (95% CI 15, 62) at 3 years. No conclusions can be drawn with regard to graftversus-lymphoma (GvLy) effect because of the high early NRM, which resulted in low patient numbers analysable for disease response and relapse. Moreover, there are a number of reports of a GvLy effect for cutaneous T-cell lymphoma, and further investigation is warranted to establish if this effect extends to other PTCL. 23 One potential way to reduce the high transplant-related mortality rate would be to employ an RIC, which would facilitate engraftment as a platform upon which to develop the GvLy effect, including the programmed use of donor lymphocyte infusions. 19, 24 Corradini et al. 12 reported prospectively on 17 patients with relapsed/primary refractory T-cell lymphomas treated with RIC Allo-SCT. Estimated 3-year OS and PFS were promising at 81 and 64%, respectively, with low NRM estimated 6% at 2 years. In conclusion, given the limitations of a retrospective analysis and the difficulties associated with an International collaborative study in a relatively rare haematological malignancy, this multi-national study does demonstrates that high-dose chemotherapy with autologous stem cell rescue has a substantial role in the management of PTCL provided patients demonstrate chemotherapy-sensitive disease. The use of full-intensity allogeneic transplantation is limited by a very high transplant-related mortality, and the development of RIC investigational protocols is desired, although given the relative rarity of the condition, such studies would benefit from multi-centre, multi-national participation to ensure sufficient statistical power to conclude clinically useful guidance of the role of allo-SCT in the management of PTCL.
